Table 1 Serologic positivity at follow-up by vaccine received and category of SARS-CoV-2 exposure and infection.
Anti-S IgA | Anti-S IgG | Anti-N IgG | |
|---|---|---|---|
COVID-19 vaccine specified* | |||
Pfizer (n = 161) | 149 (92%) | 155 (96%) | 15 (9%) |
Moderna (n = 321) | 301 (94%) | 304 (95%) | 30 (9%) |
Vaccine status | |||
Complete (n = 378) | 364 (96%) | 373 (99%) | 35 (9%) |
Partial (n = 108) | 89 (82%) | 90 (83%) | 10 (9%) |
Naïve (n = 520) | 72 (14%) | 66 (12%) | 30 (6%) |
SARS-CoV-2 exposure/infection** | |||
Definite COVID-19 (n = 58) | 56 (97%) | 55 (95%) | 20 (34%) |
Probable COVID-19 (n = 69) | 65 (94%) | 69 (100%) | 8 (12%) |
Possible COVID-19 (n = 24) | 23 (96%) | 22 (92%) | 17 (71%) |
Definite asymptomatic infection (n = 6) | 6 (100%) | 6 (100%) | – |
Possible asymptomatic infection (n = 31) | 29 (94%) | 29 (94%) | – |
No evidence of SARS-CoV-2 infection (n = 298) | 274 (92%) | 282 (95%) | – |
Prior SARS-CoV-2 infection (n = 136)*,** | 127 (93%) | 130 (96%) | 28 (21%) |
